New, Ground Breaking Research Shows Promising Advancements in the Battle Against Articular Cartilage Disease

Share Article

A new study, presented this week at the 9th World Congress of the International Cartilage Repair Society conference in Barcelona, Spain revealed that chondron density can increase in response to non-ablation radiofrequency energy. Articular cartilage disease is a large and growing problem as the US population ages. Orthopedic surgeons are able to visibly see the disease progressing but have had limited options to stop the loss of chondron density.

New, ground breaking research shows promising advancements in the battle against articular cartilage disease. A new study, presented this week at the 9th World Congress of the International Cartilage Repair Society conference in Barcelona, Spain revealed that chondron density can increase in response to non-ablation radiofrequency energy.

Articular cartilage disease is a large and growing problem as the US population ages. Orthopedic surgeons are able to visibly see the disease progressing but have had limited options to stop the loss of chondron density.

This new research, presented to a gathering of many of the world's top cartilage researchers and orthopedic surgeons, examined how non-ablative radiofrequency energy can preferentially increase articular cartilage Superficial Zone live chondron density. Resetting functional chondron density patterns may have the potential to create a more chondro-supportive environment for articular cartilage as it inherently responds to disease.

Dr. Jack Farr, a leading orthopedic surgeon out of Indianapolis stated, “The research presented at the conference shows a compelling case for a new treatment option we now have for articular cartilage disease. This non-ablative technology now allows us to selectively target and remove damaged tissue without causing necrosis in the contiguous cartilage tissue surrounding the lesion. This is an important step forward.”

NuOrtho Surgical, Inc is the medical device company that developed and sells the new non-ablative RF energy surgical probe used in the study. NuOrtho CEO, Jeff Morrill, released the following statement,
"Ceruleau® is the product used in the study to achieve these promising results. The opportunity to achieve successful early surgical intervention for articular cartilage lesions rather than waiting for full-thickness lesions to develop has recently been made possible with the advent of non-ablation radiofrequency technology and Ceruleau®. With our recent FDA clearance for Ceruleau®, we are excited to bring this surgical tool to orthopedic surgeons."

Additional information on the ICRS presentation as well as further details of the study can be found at:
http://posters.webges.com/get/pdf/icrs2010/3754/

NuOrtho Surgical is focused on surgical instruments to enable Tissue Preservation℠ in the orthopedic arena to improve patient outcomes. The technology leverages a low level Radio Frequency energy to restore mobility in patients by preserving healthy tissue in both soft and hard tissue procedures. NuOrtho has three primary product platforms for preserving healthy Tissue to sustain long-term mobility in our busy lives, particularly for Baby Boomers. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. More information can be found at http://www.nuorthosurgical.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Heye
Visit website